PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
21521254-3	2011	This prospective study investigates effect of 6-month treatment with octreotide long-acting repeatable (LAR) on insulin-like growth factor-1 (IGF-1) and growth hormone (GH) levels, pituitary function, tumour regression and postoperative cure in de novo acromegalic patients.	Octreotide	69-79	growth hormone 1	Homo sapiens	153-167	
21521254-8	2011	The GH reduction following an acute octreotide test was 81 +- 19% and associated with long-term GH reduction (r = 0 78, P < 0 0005).	Octreotide	36-46	growth hormone 1	Homo sapiens	4-6	
21521254-8	2011	The GH reduction following an acute octreotide test was 81 +- 19% and associated with long-term GH reduction (r = 0 78, P < 0 0005).	Octreotide	36-46	growth hormone 1	Homo sapiens	96-98